新型化合物用于向α1-上腺素受体,用于抗高血压治疗
Sunil Sahu1, Pankaj Minj1, Dhansay Dewangan2
1University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, 492010, India.
Cardiovascular & hematological agents in medicinal chemistry
|October 6, 2025
概括
新的α1-adrenoceptor对抗剂可以改善高血压的管理. 研究人员审查了新型化合物,重点关注结构-活性关系和亚型选择性,以改善心血管药物开发.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 药用化学 医学化学
背景情况:
- 高血压是一个日益严重的全球健康问题,特别是在低收入和中等收入国家,增加中风和心脏病发作的风险.
- 阿尔法1-上腺体受体对抗剂是抗高血压药物的关键类别,但现有的选择如现在osin具有显著的副作用.
- 新型α1-上腺抗剂正在开发中,以提高治疗的疗效和安全性.
研究的目的:
- 审查最近合成的α1-adrenoceptor对抗剂用于高血压管理.
- 分析这些新型化合物的结构-活性关系.
- 评估它们对向治疗效果的亚型选择性.
主要方法:
- 关于最近合成的α1-腺素受体对抗剂的文献综述.
- 基于已公布的数据,分析结构-活动关系 (SAR).
- 评估审查的化合物的亚型选择性概况.
主要成果:
- 通过修改诸如Isochroman-4-one, Quinazolines和Piperazine之类的药,合成了几种新的α1-上腺抗剂.
- 这些新化合物显示出改善抗高血压活性的潜力.
- 重点是了解SAR和亚型选择性,以指导未来的药物设计.
结论:
- 新型α1-腺素受体对抗剂代表了开发更安全,更有效的高血压治疗的有前途领域.
- 进一步研究SAR和亚型选择性对于优化这些药物至关重要.
- 这些进展可能会导致更好的高血压管理和降低心血管风险.
相关概念视频
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.5K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.5K
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.3K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.3K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
01:30Adrenergic Agonists: Direct-Acting Agents
2.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932